RNA startup led by Pfizer vets closes $52M investment round


Rgenta Therapeutics, a startup behind RNA-targeting small molecules for "undruggable" diseases, has raised another $52 million as it works to enter clinical trials in the next three years.

Previous From Van Gogh to Disney: Lighthouse Artspace producer discusses latest 'Immersive' exhibit
Next Akram Boutros sues MetroHealth board, chairwoman over his firing